Seattle Genetics's top competitors are Almac, AbbVie and Ambrx. Find the latest press releases from Seattle Genetics, Inc. Common Stock (SGEN) at Nasdaq.com.

View all news. June 8, 2020 Seattle Genetics … Advanced Search. Follow. 06/18/2020. Do the numbers hold clues to what lies ahead for the stock? Seattle Genetics is dedicated to improving patient outcomes with advanced antibody-drug conjugate technology delivering cancer-killing therapy to tumor cells. Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates. Advanced Search. Seattle Genetics Articles. VIsit this page to view recent news, quick facts about Seattle Genetics, and access available resources, logos, videos, and email alerts. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the … Sign Up.

See Seattle Genetics's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform. See Seattle Genetics's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform.

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 20.99% and 10.58%, respectively, for the quarter ended March 2020. Seattle Genetics's top competitors are Almac, AbbVie and Ambrx. Seattle Genetics Articles. Followed Companies. Followed Companies. Find the latest Seattle Genetics, Inc. (SGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. Advanced Search. Articles. Articles. Seattle Genetics to Present at Goldman Sachs 41st Annual Global Healthcare Conference finance.yahoo.com - June 3 at 9:10 AM: Seattle Genetics (NASDAQ:SGEN) Earns "Buy" Rating from Oppenheimer www.americanbankingnews.com - May 31 at 8:24 PM: Seattle Genetics (NASDAQ:SGEN) Stock Rating Reaffirmed by Oppenheimer www.marketbeat.com - May 31 at 7:39 PM
Find the latest news headlines from Seattle Genetics, Inc. Common Stock (SGEN) at Nasdaq.com. Follow. All News Blogs Videos Press Releases. "One of the most attractive growth stories in biotech," says analyst Salveen Richter, lifting the price target on Seattle Genetics (NASDAQ:SGEN) to a Street-high … Newsfeed. All News Blogs Videos Press Releases. June 8, 2020 Seattle Genetics …

Sign Up. Advanced Search. Seattle Genetics Inc's add-on therapy for an advanced form of breast cancer that has progressed despite prior treatment was on Friday approved months ahead of … Newsfeed. Real time Seattle Genetics (SGEN) stock price quote, stock graph, news & analysis.